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Introduction: The worldwide shortage of donor livers has prompted the search for alternative cell therapies.
Previous data from our laboratory proved a supportive role for stem cell therapy in the treatment of end-stage liver
disease patients. Therefore; this study was conducted to assess the clinical and biochemical effects of repeated stem
cell infusion.
Methods: Ninety patients with liver cirrhosis were randomized to receive either one session treatment (G-I) or two
sessions 4 months apart (G-II) of autologous haematopoietic stem cells (HSCs) transplantation and a control group
(G-III) who received regular liver treatment. G-CSF was administered to transplanted patients before infusion; HSCs
were isolated from 400 cc bone marrow (BM) aspirate. CD34+/CD133+ cells were purified: 50 % of the cells were
infused locally in the portal vein on the same day and the other 50 % were differentiated to MSC and infused
systemically in a peripheral vein (one session treatment G-I). In G-II, the same process was repeated after 4 months
from the first treatment (two session’s treatment G-II). Liver function was monitored for 12 months after stem cell
therapy (SCT).
Results: Statistically significant improvement was reported in the transplanted patients (G-1) as regards the mean
serum albumin, bilirubin and INR levels which started to improve after 2 weeks of treatment and continued to
improve till the 6th month in the single infusion group. The two sessions infused group (G-II) showed sustained
response which continued throughout the all follow-up period (12 month). By the end of the study, 36.7 % of the
patients in G-I and 66.7 % in G-II showed improvement in the degree of ascites compared to the control group
(G-III). We also reported an improvement in the hepatic functional reserve as assessed by the Child-Pugh and MELD
score. Safety of the procedure was evidenced by the low incidence of complications encountered.
Conclusion: In patients with end-stage liver disease, the repeated infusion with combined routes portal and peripheral
veins has a beneficial effect on liver functions with minimal adverse events and more lasting clinical efficacy after
repeated HSCs infusion.Introduction
Cirrhosis, the end result of long-term liver damage, and
its related morbidity place a significant burden on health
care worldwide. Liver transplantation is the only defini-
tive therapeutic option for these patients. However, the
paucity of donors, rejection and the high costs are* Correspondence: ncizekri@yahoo.com
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ticularly the adult haematopoietic stem cell (HSC)-based
therapies, are evolving as viable clinical alternatives [1].
Stem cells are clonogenic, self-renewing cells, capable
of differentiating into multiple cell lineages [2]. During
tissue injury, bone marrow stem cells (BMSCs) are mo-
bilized and migrate to the injured organ. This has
formed the basis for regenerative therapy whereby treat-
ment with appropriate stem cells might ameliorate spe-
cific diseases [3].cle distributed under the terms of the Creative Commons Attribution License
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from bone marrow (BM) cell populations, and further
advances in the understanding of HSC plasticity, have
formed the basis for stem cell therapy in patients with
liver disease [4–6]. However, the mechanism by which
HSCs contribute to liver repair is controversial. Initial
studies suggested that adult stem cell plasticity and their
differentiation to hepatocytes is a possible mechanism of
action [7]. Other studies have shown that conversion to
hepatocytes may occur via cell fusion [8].
Animal studies demonstrate that infusion of BM dur-
ing liver injury reduces the amount of liver scarring,
owing to matrix metalloproteinase-9 expression [9]. Re-
cently, the concept of stem cell infusions exerting a
paracrine proliferative effect on endogenous hepatocytes
has been gaining support, backed up by rodent and hu-
man studies [10, 11].
In Egypt, results obtained from several studies suggested
that autologous CD34+ cell transplantation offered consid-
erable improvement in the quality of life and liver func-
tions in patients with viral or non-viral causes of end-
stage liver disease with no procedure-related complica-
tions [12]. However, it was observed that serum albumin,
bilirubin and International Normalized Ratio (INR) levels
had gradually worsened towards pre-infusion levels after
an initial improvement for about 3–6 months, especially
in patients with viral aetiologies [13].
The inability to maintain the initial improvement in
those patients could be attributed, at least potentially,
to the ongoing disease processes affecting the regener-
ated hepatocytes over a longer period. Therefore, in
order to maintain benefit of such therapies, it may be
important to treat the causative disease, such as viralFig. 1 Stem cell treatment schedule of patients who received one session.hepatitis, to make the infused cells resistant to viral in-
fection [14] or to repeat the injection of stem cells at
intervals to achieve significant and lasting clinical re-
sults [15].
Currently, there are no published trials regarding the
beneficial effect of repeated infusion of HSCs in liver
disease. However, repeated infusion of BM cells in pa-
tients with large acute myocardial infarction resulted in
a significant increase in left ventricular ejection fraction
and a decrease in myocardial infarct size compared with
single intracoronary injection [16].
Methods
Studied groups
This prospective study included 90 patients with hepa-
titis C virus (HCV)-associated liver cirrhosis who were
eligible for treatment intervention. Patients were re-
cruited from the Tropical Medicine Department, Cairo
University Hospital, Cairo, Egypt during the period from
May 2010 to May 2012. Written informed consent was
obtained from each patient included in the study regard-
ing the study plan or publication.
Patients were randomized into one of three groups:
1. Group 1 (G-I: one-session treatment) included 30
patients who received one-session treatment of
autologous HSC transplantation, as illustrated in
Fig. 1.
2. Group 2 (G-II: double-session treatment) included
30 patients who received two sessions of autologous
HSC transplantation 4 months apart (Fig. 2).
3. Group 3 (G-III: control group) included 30 patients
who received regular liver treatment only.BM bone marrow, G-CSF, MSC mesenchymal stem cell
Fig. 2 Stem cell treatment schedule of patients who received two sessions. BM bone marrow, G-CSF, MSC mesenchymal stem cell
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least 48 weeks or until they died.Inclusion criteria
Patients included in the study fulfilled the following cri-
teria: male or female, age range from 20 to 60 years, evi-
dence of chronic liver insufficiency (decreased s-albumin
and/or increased bilirubin and/or increased INR, Child–
Pugh scores B and C and Model for End-Stage Liver Dis-
ease (MELD) scores >14) and who cannot receive a liver
transplant owing to organ shortage and/or high cost of
liver transplantation in Egypt. All had a World Health
Organization (WHO) performance score ≤2 and were able
to give written informed consent. All patients were post-
HCV infection with viral load ranging from 3690 to
954,473 IU (mean = 523,764 IU). Some patients received
interferon/ribavirin with no response (16 patients were
previously non-responders in group I, five patients in
group II and six patients in the control group), and others
did not receive previous interferon therapy.
To manage HCV in the control group the participants
were given virostatic drugs only (ribavirin and amanta-
dine sulphate), and for ascites they received a diuretic
combination (furosemide and spironolactone) with thera-
peutic paracentesis for some of them. Patients with grade
III–IV varices who showed signs of impending rupture
prophylactic sclerotherapy and/or band ligation under-
went treatment before stem cell therapy. No hepatitis B
virus cases were recruited. All patients were negative for
portal tract thickening that is characteristic for schisto-
somiasis. No liver biopsies were performed to decrease
the probability of complications since the aim of the
current study is to assess the improvement in the syn-
thetic function of the liver and not to assess the fibrotic
process within the liver.Exclusion criteria
Patients were excluded from the study if they: were aged
younger than 20 or older than 60 years; were pregnant or
lactating women; had recent and/or recurrent upper gastro-
intestinal bleeding or spontaneous bacterial peritonitis (SBP)
within 1 month before the procedure or hepatocellular
carcinoma (HCC); were patients with portal vein thrombosis
(PVT) on Doppler ultrasonography or severe co-morbid
diseases (e.g. renal or cardiac disease); had evidence of hu-
man immunodeficiency virus or other life-threatening in-
fection; were unable to give written consent; had a history
of hypersensitivity to granulocyte colony-stimulating
factor (G-CSF); or were included in any other clinical trial
within the previous 6 months.
Patients in the three groups were comparable for base-
line characteristics including age and sex, aetiology of
liver disease and MELD score. Clinical evaluation was
carried out for all patients, including a detailed medical
history and complete clinical examination with special
emphasis on the presence of an evidence for liver cell
failure (e.g. ascites), jaundice, lower limb oedema, bleed-
ing tendency, or signs of encephalopathy in addition to
the WHO performance score.
Laboratory investigations were done for all patients in-
cluding the liver biochemical profile (s-bilirubin, s-
albumin, INR, alanine transaminase (ALT) and aspartate
transaminase (AST)), serum creatinine levels, complete
blood count (haemoglobin, white blood cell count, plate-
let count), coagulation profile (INR), α-fetoprotein (AFP)
and hepatitis serological profile (hepatitis B surface anti-
gen (HBsAg), hepatitis B core antibody (HBcAb), HCV-
antibody and HCV-RNA by quantitative PCR and HIV by
ELISA). Abdominal ultrasound scanning was performed for
the three groups using a Hitachi 515 (Chiyoda, Tokyo,
Japan) real-time scan after overnight fasting (before and fol-
lowing HSC transplantation), and the MELD score and
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hepatic decompensation for every patient. Computed tom-
ography (CT) scan, Doppler scan and upper gastrointestinal
endoscopy were performed before stem cell transplantation.
Ethics
The ethical committees of Kaser El-Aini School of Medi-
cine and the National Cancer Institute, Cairo University
approved the study protocol, which was in accordance
with the Declaration of Helsinki and written informed
consent was obtained from each patient prior to enrol-
ment in the study. WHO Universal Trial Number: U1111-
1134-8652. ClinicalTrials.gov: NCT01729221. Registered
17 November 2012, study start January 2010.
Treatment sessions
 G-CSF injection. Patients from G-I and G-II received a
daily subcutaneous injection of G-CSF given as filgras-
tim 300 μg (Neupogen® 1 ml vial; Roche Products
(New Zealand) Limited PO Box 109113 Newmar-
ket Auckland 1149 New Zealand) for 5 days to in-
crease the number of circulating HSCs. All patients
were screened at days 1, 3 and 5 by clinical assessment
for adverse effects and laboratory investigations (blood
count and liver biochemical profile)
 BM stem cell aspiration. After 5 days of G-CSF injec-
tions, a standard BM aspiration procedure was per-
formed by a trained haemato-oncologist. The patient’s
skin was cleaned with 70 % alcohol at the iliac crest,
which is the usual site for puncture in adults. The
skin, subcutaneous tissues and periosteum overlying
the selected site for puncture were infiltrated with
xylocaine local anaesthesia and serial punctures
from multiple sites were performed. With a boring
movement, needles (Salah and Klima New Delhi -
110055, Delhi, India) were passed perpendicularly into
the cavity of the ileum at a point just posterior to the
anterior superior iliac spine or 2 cm posterior and 2 cm
inferior to the anterior superior iliac spine to aspirate
400 ml BM into a sterile heparin-coated container.
The collected BM products were transferred to the
stem cell laboratory for immuno-magnetic purifica-
tion of the CD34+ and CD133+ stem cell population
using the positive cell selection kit (MACS System Mil-
teny Biotec, Gmbh, Bergisch Gladbach Germany) [17].
The isolated CD34+/CD133+ cells were washed twice
with phosphate-buffered saline (pH 7.4) supplemented
with 0.5 % bovine serum albumin and 5 mmol/l ethyl-
enediamine tetraacetic acid, and centrifuged at
1500 rpm for 10 minutes at 4 °C. Cells were counted,
adjusted to 1 × 108, centrifuged and re-suspended in
100 ml physiological saline. On the same day, 50 % of
the cells (0.5 × 108) were infused locally undersonographic guide in the portal vein and the other 50 %
were cultured for mesenchymal stem cell (MSC)
differentiation.
 MSC differentiation. CD34+/CD133+ cells were cultured
in DMEM/HamF12/MSC media (25 %/25 %/50 %)
containing 10 % bovine serum albumin (Invitrogen
Waltham, Massachusetts, USA), 1 % penicillin/
streptomycin (Invitrogen Waltham, Massachusetts,
USA), 1 ng/ml G-CSF, hepatocyte growth factor (5 ng/
ml H1404; Sigma, Virginia, USA.) and liver extract
(10 ng/ml, G7387; Sigma). Cells were incubated for 5–7
days at 37 °C in 5 % CO2 and examined with phase
contrast microscopy for morphological changes
characteristic of MSC differentiation. In the current
study, a critical point for successful differentiation into
MSCs was the relation between the number of cultured
cells, the surface area of the tissue culture flasks used
and the amount of the tissue culture media [18].
 Characterization of cultured cells. Cells were
periodically examined with a phase contrast
microscopy for morphological changes indicating
trans-differentiation into MSCs. Aliquots of cultured
cells were obtained for immunophenotypic
characterization by flow cytometry using surface
MSC markers (CD44-FITC, CD90-PerCP, CD29-
FITC and CD105y versus CD45-PE). Cells were
considered MSCs if they were negative for CD45-PE
and positive for CD44-FITC, CD90-PerCP, CD29-
FITC and CD105y (either one or all of them)
 Injection of trans-differentiated MSCs. On day 7 post
BM aspiration, patients were admitted to hospital while
fasting for intravenous infusion with approximately
1 × 106/kg body weight of the expanded MSCs:
(A)Treatment protocol for G-I: one-session based
treatment as described above.
(B) Treatment protocol for G-II: two-session based
treatment as described above with a 4-month
interval between the two sessions. Both sessions
have similar procedure and dose of infused cells.
(C)Treatment protocol for G-III (regular liver
treatment): patients received their usual, regular
supportive liver treatment.
 Follow-up of patients after MSC infusion. All patients in
the three groups were followed up every hour for
24 hours, then weekly for the first month and monthly
for 12 months. During the follow-up the patients were
observed for clinical improvement through assessing
the degree of fluid retention (ascites and lower limb
edema), performance status and score. Some patients
recorded a few complications such as mild bony aches
and low-grade fever after receiving G-CSF which sub-
sided spontaneously. Biochemical assessment included
s-bilirubin and albumin, prothrombin time and concen-
tration, INR, ALTand AST, s-creatinine levels and
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Child–Pugh score progression.
Statistical analysis
All patients’ data were tabulated and processed by SPSS
(Statistical Package for Science and Society) version 12.0
for Windows XP (Seattle, Washington, US). Descriptive
statistics were presented as mean ± standard deviation for
quantitative variables, whereas qualitative data were
expressed as frequency (number) and percent. Compari-
sons between groups were carried out using the chi-
square test, Fischer’s exact test or McNemar test when ap-
propriate for qualitative data. Independent-sample t test
and paired-sample t test were used for normally distrib-
uted quantitative variables. The non-parametric Mann–
Whitney test and the Wilcoxon singed-rank test were
used for abnormally distributed quantitative variables. Per-
cent changes in prognostic variables were calculated and
compared using the Mann–Whitney test. P <0.05 was
considered statistically significant. Linear regression ana-
lysis was employed to determine the degree of improve-
ment of the clinical features in relation to response to
treatment.
Results
The baseline clinical, ultrasonographic and endoscopic
features of all studied groups are illustrated in Tables 1,
2 and 3.Table 1 Baseline laboratory and clinical investigations of the studied
Control group
Age (years) 49.43 ± 4.53
Male 26 (86.7 %)
Female 4 (13.3 %)
Haemoglobin (g/dl) 10.33 ± 1.06
TLC (1000/cm) 6.07 ± 1.64
Platelets (1000/cm) 104 ± 34
Total bilirubin (N: 0.1–1 mg/dl) 3.19 ± 0.89
Serum albumin (N: 3.4–5.2 g/dl) 2.8 ± 0.15
INR (N: 1) 1.67 ± 0.16
ALT folds (N: 0–41 IU) 33.3 ± 16.75
AST folds (N: 0–37 IU) 40.63 ± 25.37
AFP 5.4 ± 3.21
Serum creatinine (0.7–1.2 mg/dl) 1.05 ± 0.15
Jaundice 18 (60 %)
Encephalopathy 14 (46.7 %)
Lower limb oedema 20 (67.7 %)
Bleeding tendency 23 (76.7 %)
Haematemesis 14 (46.7 %)
Data presented as number (percent) or mean ± standard deviation. None of these p
AFP α-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, INBoth single and double shot-treated patients showed
increased s-albumin 2 weeks after infusion, with consist-
ent increase after 1, 2, 3 and 4 months. As for the single
infusion group, s-albumin started to decline after
12 months. The double infused group kept the s-
albumin level and almost reached the normal value
(3.39 ± 0.21). The difference between the two groups was
statistically significant (P = 0.00) (Fig. 3 and Table 4).
Similarly, there was a statistically significant improve-
ment in bilirubin level and INR in the double-infused
patients compared with the single-infused patients and
control group after 12 months of follow-up (Table 4 and
Figs. 4 and 5). However, no statistically significant differ-
ence was found between both studied groups regarding
the renal functions at baseline and all through the study.
At the end of the study, 12 patients (40 %) showed im-
provement in their Child–Pugh grade compared with
the baseline (P = 0.05) (Table 5 and Fig. 6). Similarly,
there was an improvement in the MELD score of the
double-infused group (17.23 ± 1.33) rather than both the
control and the single-infused groups at the beginning
of the study compared with that at 12 months in the
double-infused group (13.96 ± 1.59) compared with the
single-infused group (14.96 ± 2.39) and the control group
(16.32 ± 3.70) (P = 0.0001) (Table 6 and Fig. 7).
At the end of the study, 66.7 % of the patients in G-II
showed improvement in their ascites compared with
36.7 % in G-I (P = 0.001) (Table 7 and Fig. 8). Changesgroups
Single infusion Repeated infusion P value
49.63 ± 4.58 50.97 ± 4.15 1.00
25 (83.3 %) 26 (86.7 %) 0.923
5 (16.7 %) 4 (13.3 %) 0983
10.2 ± 1.48 10.3 ± 0.77 0.614
5.17 ± 2.05 6.07 ± 1.14 0.520
104 ± 55 104 ± 37 0.542
3.59 ± 0.79 3.16 ± 0.99 0.326
2.57 ± 0.15 2.83 ± 0.16 0.291
1.76 ± 0.22 1.68 ± 0.17 0.504
32.9 ± 15.07 33.3 ± 18.82 0.975
41 ± 20.31 40 ± 29.79 0.401
8 ± 3.79 5.4 ± 2.63 0.816
0.92 ± 0.23 1.04 ± 0.30 0.841
22 (73.3 %) 21 (70 %) 0.26
12 (40 %) 13 (43.3 %) 0.81
20 (67.7 %) 19 (63.3 %) 0.45
24 (80 %) 22 (73.3 %) 0.56
13 (43.3 %) 15 (50 %) 0.82
arameters showed significant differences among the three groups
R International Normalized Ratio, TLC total leucocyte count
Table 2 Ultrasonographic features of the studied groups
Control group Single infusion Repeated infusion P value
N % N % N %
Liver size
Average 6 20 6 20 8 26.7 1.00
Shrunken 24 80 24 80 22 73.3
Liver texture
Cirrhotic 30 100 30 100 30 100
Spleen
Average sized 0 0 0 0 0 0 0.427
Mild splenomegaly 12 40 18 60 24 80
Moderate splenomegaly 18 60 12 40 6 20
Ascites
Absent 13 43.3 9 30 12 40 0.274
Mild 5 16.7 6 20 6 20
Moderate 8 26.7 10 33.3 8 26.7
Massive 4 13.3 5 16.7 4 13.3
Portal vein
Patent 30 100 30 100 30 100
None of these parameters showed significant differences among the three groups
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abdominal girth and the body weight of the patients as
well as by repeated ultrasonography during the follow-
up. Ascites was categorized as: (1) mild if localized in
the pelvis and/or hepatorenal angle only, (2) moderate if
it reaches the mid-abdomen or (3) massive if more than
this. On the other hand, there was a significant reduc-
tion in the tapping of ascites in G-II patients after 9 and
12 months; respectively compared with 15 % in G-I and
32 % in the control group (P = 0.58).
The correction in portal hypertension, which occurred
as a consequence of the anti-fibrotic effect of the infused
MSCs, was not rapid. This effect together with the im-
provement in albumin level can explain the good re-
sponse in ascites, but for portal hypertension and
variceal size to change this will probably need a longerTable 3 Endoscopic features of the studied groups
Endoscopic findings Control group Single infusion
N % N
Varices
None 3 10 5
Grade I 14 46.7 6
Grade II 6 20 9
Grade III 6 20 6
Grade IV 1 3.3 4
Congestive gastropathy 24 80 23
P >0.05 is not statistically significant, between the control and study grouptime of follow-up and may require repeated MSC infu-
sion at different time intervals.
During the whole follow-up period there was no statis-
tically significant difference between both studied groups
regarding hepatic encephalopathy in spite of the remark-
able improvement in the synthetic liver function as
shown in Table 8. This is explainable since stem cells
have no effect on the porto-systemic collaterals that shift
ammonia away from the liver to the brain.
Survival analysis
The mortality rate in G-I (single infusion group) was
10 % (three patients, two of them died of hepatorenal
syndrome (HRS) type 1 and one patient died due to un-
controlled attack of haematemesis). In G-II (repeated in-
fusion), the mortality rate was 6.7 % (two patients): oneP value Repeated infusion P value
% N %
16.7 0.29 4 13.3 0.8
20 0.091 14 46.7 0.4
30 0.4 6 20 0.2
20 0.25 3 10 0.31
13.3 0.37 3 10 0.2
76.7 0.28 22 73.3 0.3
Fig. 3 Changes in serum albumin in the studied groups before infusion, after 2 weeks and 1, 2, 3, 6, 9 and 12 months
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attack of haematemesis. In the control group, the mor-
tality rate was 16.5 % (five patients): two from HRS type
1, two from septic shock (following an episode of SBP)
and one from an uncontrolled attack of haematemesis as
shown in Table 8.Table 4 Biochemical changes in the studied groups
Pre treatment 2 weeks 1 month 2 m
Albumin
Control 2.80 ± 0.15 2.80 ± 0.14 2.75 ± 0.19 2.73
Single infusion 2.58 ± 0.15 2.70 ± 0.22 2.79 ± 0.22 2.90
Double infusion 2.84 ± 0.17 2.95 ± 0.13# 3.04 ± 0.14# 3.16
s-Bilirubin
Control 3.19 ± 0.89 3.23 ± 0.87 3.31 ± 0.92 3.32
Single infusion 3.59 ± 0.79 3.43 ± 0.77 3.39 ± 0.76 3.29
Double infusion 3.16 ± 0.99 3.07 ± 0.95 3.03 ± 0.96 2.96
INR
Control 1.67 ± 0.16 1.62 ± 0.19 1.61 ± 0.21 1.67
Single infusion 1.76 ± 0.22 1.60 ± 0.32 1.54 ± 0.33 1.46
Double infusion 1.68 ± 0.17 1.60 ± 0.20 1.57 ± 0.22 1.53
Serum creatinine
Control 1.06 ± 0.15 0.95 ± 0.10 0.94
Single infusion 0.92 ± 0.13 0.90 ± 0.15 0.92
Repeated infusion 1.04 ± 0.16 0.93 ± 0.10 0.91
Data presented as mean ± standard deviation
*P <0.05 between single infusion or repeated infusion groups and the control grou
#P <0.05 between the single infusion and repeated infusion groupsDiscussion
Pegylated interferon alpha and ribavirin are effective
against HCV in the treatment-naïve patients, with sus-
tained viral response of about 60 % in genotype 4 with
undesirable adverse effects. However, these regimens are
not eligible for many patients, and they are associatedonths 3 months 6 months 9 months 12 months
± 0.18 2.71 ± 0.21 2.68 ± 0.22 2.66 ± 0.22 2.64 ± 0.19
± 0.24* 2.96 ± 0.35* 2.98 ± 0.33* 2.95 ± 0.33* 2.88 ± 0.30*
± 0.14#* 3.28 ± 0.17#* 3.36 ± 0.20#* 3.39 ± 0.20#* 3.39 ± 0.21#*
± 0.92 3.33 ± 0.92 3.36 ± 0.91 3.30 ± 0.88 3.24 ± 0.78
± 0.83 3.18 ± 0.88 3.10 ± 0.93* 3.16 ± 0.81 3.18 ± 0.84#
± 0.94 2.86 ± 0.98* 2.76 ± 0.98#* 2.77 ± 1.00#* 2.75 ± 0.98#*
± 0.19 1.73 ± 0.19 1.73 ± 0.21 1.74 ± 0.20 1.72 ± 0.20
± 0.34* 1.42 ± 0.36* 1.44 ± 0.34* 1.46 ± 0.29* 1.49 ± 0.28*
± 0.22 1.49 ± 0.16* 1.44 ± 0.17* 1.43 ± 0.18* 1.41 ± 0.15*
± 0.06 0.95 ± 0.09 0.96 ± 0.14 0.95 ± 0.11 0.93 ± 0.99
± 0.17 0.88 ± 0.16 0.89 ± 0.16 0.91 ± 0.12 0.89 ± 0.11
± 0.11 0.91 ± 0.09 0.90 ± 0.13 0.91 ± 0.22 0.92 ± 0.13
p
Fig. 4 Changes in serum bilirubin in the studied groups before infusion, after 2 weeks and 1, 2, 3, 6, 9 and 12 months
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tients. Pegylated interferon was not used in the current
study, since most of our cases were Child–Pugh score C
where interferon has a limited effect with many side ef-
fects. On the other hand, the second generation (sofos-
buvier, semiprivir) is not yet available in Egypt. Patients
were therefore maintained on suppressive therapy using
ribavirin and amantadine.
Liver cirrhosis represents the end result of chronic
liver disease and is a major cause of mortality worldwide
[19]. In Egypt, HCV-associated liver disease is a national
health problem causing considerable morbidity and mor-
tality [20].Fig. 5 Changes in International Normalized Ratio (INR) in the studied grouLiver transplantation is the only curative treatment for
decompensated cirrhosis, but it is limited by technical
difficulties, high cost and lack of donors [21]. Other treat-
ment modalities for decompensated cirrhosis are only
symptomatic with transient improvement of the quality of
life [22]. Consequently, the majority of untransplanted pa-
tients die while waiting for transplantation. Therefore, it is
necessary to develop new therapeutic modalities for pa-
tients with chronic liver disease.
Cell-based therapy, including stem cell therapy, offers
considerable hope for these patients since the stem
cells, including BM-derived stem cells, have the capacity
for self-renewal and multi-lineage differentiation [23].ps before infusion, after 2 weeks and 1, 2, 3, 6, 9 and 12 months
Table 5 Progress of Child–Pugh score in the studied groups after 1, 2, 3, 6, 9 and 12 months of infusion
Child–Pugh A Child–Pugh B Child–Pugh C χ2 P value
Single infusion Double infusion Single infusion Double infusion Single infusion Double infusion
Pre-treatment 0 (0) 0 (0) 12 (40) 18 (60) 18 (60) 12 (40) 9.73 0.259
1 month 0 (0) 1 (3.3) 22 (73.3) 26 (86.7) 8 (26.7) 3 (10) 4.72 0.03
2 months 0 (0) 1 (3.3) 24 (80) 28 (93.3) 6 (20) 1 (3.3) 4.59 0.03
3 months 1 (3.3) 3 (10) 25 (83.3) 27 (90) 3 (10) 0 (0) 1.03 0.03
6 months 1 (3.3) 7 (23.3) 24 (80) 23 (76.7) 3 (10) 0 (0) 1.43 0.03
9 months 0 (0) 8 (26.7) 24 (80) 21 (70) 4 (13.3) 0 (0) 1.54 0.04
12 months 0 (0) 7 (23.3) 23 (76.7) 20 (67) 4 (13.3) 1 (3.3) 3.37 0.05*
Data presented as count (%)
*There is a statistically significant difference between the repeated-infusion and the single-infusion groups (P ≤0.05)
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mass and function, alleviate fibrosis and correct inher-
ited diseases [24]. In addition, patients receiving autolo-
gous BMSCs demonstrated considerable improvement
in their laboratory data and quality of life, with no
procedure-related complications [25]. However, the in-
ability to maintain the initial response could be due to
the ongoing disease process which affects the regener-
ated hepatocytes over a long period. Therefore, in order
to maintain the effect of such therapies, it may be im-
portant to treat the causative liver disease, such as viral
hepatitis, to make the infused cells resistant to viralFig. 6 a Child–Pugh score in group III patients (control group). b Child–Pu
group II patients (repeated infusion)infection [14] or to repeat the injection of stem cells at
intervals to achieve sustained response [15] as previ-
ously reported in patients with large acute myocardial
infarction [16].
We therefore sought to assess the effectiveness of HSC
transplantation when given through two different routes
in combination (peripherally and intra-portal vein) or se-
quentially (4 months apart) compared with the single-
infusion procedure.
We found a statistically significant difference between
the single-infusion and the repeated-infusion groups re-
garding serum albumin throughout the follow-up period.gh score in group I patients (single infusion). c Child–Pugh score in
Table 6 Changes in Model for End-Stage Liver Disease score in the studied groups before infusion, after 2 weeks and 1, 2, 3, 6, 9
and 12 months
Study group Pre-treatment 1 month 2 months 3 months 6 months 9 months 12 months
Control group 17.20 ± 1.32 16.13 ± 1.54 16.47 ± 1.43 17.00 ± 1.68 17.24 ± 1.90 17.15 ± 1.95 16.32 ± 3.70
Single infusion 17.60 ± 1.90 15.73 ± 2.89 14.90 ± 3.24* 14.48 ± 3.11* 14.64 ± 2.92* 14.86 ± 2.57* 14.96 ± 2.39*
Double infusion 17.23 ± 1.33 15.53 ± 1.99 15.03 ± 1.81* 14.57 ± 1.56* 14.07 ± 1.72* 13.97 ± 1.74*# 13.96 ± 1.59*#
Data presented as mean ± standard deviation
* P <0.05 between single infusion or repeated infusion and control groups
# P <0.05 between single-infusion and repeated-infusion groups
Zekri et al. Stem Cell Research & Therapy  (2015) 6:118 Page 10 of 14The maximum improvement in s-albumin occurred after
6 months of the study in G-I and then started to decline,
whereas in G-II the improvement continued throughout
the whole follow-up period to reach a maximum at the
end of the study (after 1 year). This was also true regard-
ing s-bilirubin, which revealed maximum improvement
after 6 months in G-I (single infusion) followed by a de-
cline, whereas in G-II (repeated infusion) the improve-
ment continued throughout the follow-up period to
reach the maximum at the end of the study. Similar re-
sults were previously reported by Levicar et al. [14] and
Pai et al. [24].
Similarly, the maximum improvements in the INR and
the MELD score occurred after 3 months of infusion in
G-I (single infusion) and then started to decline, whereas
in G-II (repeated infusion) the improvement continued
throughout the follow-up period to reach the maximum
at the end of the study. Our results in this context are in
agreement with our previous studies by Salama et al.
[18, 25, 26].
Our results regarding the maximum improvement in
the Child–Pugh score which occurred after 6 months of
follow-up are comparable with Terai et al. [6] and Pai
et al. [24], who demonstrated significant improvement ofFig. 7 Changes in Model for End-Stage Liver Disease (MELD) score in the s
and 12 monthsChild–Pugh score at 4 and 24 weeks after autologous
BMSC transplantation therapy.
All patients presenting with massive ascites (five pa-
tients) showed disappearance of their ascites after
2 months from starting therapy. By the end of the study,
40 % of the patients showed improvement in the degree
of ascites, 60 % showed no change and none of the stud-
ied patients showed deterioration in their degree of asci-
tes. Our findings in this context support previously
published data [6, 24, 27].
During the follow-up period in the current study, 11
patients suffered attacks of haematemesis, which oc-
curred after 6 months of the stem cell transplantation:
four patients (13.3 %) from G-I, two patients (6.7 %)
from G-II and five patients from the control group. Two
patients were Child–Pugh score B and nine patients
were Child–Pugh score C; two of which died from un-
controlled bleeding that occurred at the 12th month. Lit-
erature review showed that transient portal hypertension
resulting from blood flow occlusion following stem cell
infusion usually resolves in 2–3 hours [28]. At the begin-
ning of the current study, there was no PVT in the stud-
ied groups. After 12 months of the study, the incidence
of PVT was 3.3 % (one patient) in G-I compared withtudied groups before infusion, after 2 weeks and 1, 2, 3, 6, 9
Table 7 Change in the degree of ascites after 3, 6, 9 and 12 months
Control group Single infusion P value Repeated infusion P value
N % N % N %
After 1 month Improved 1 3.3 11 36.7 00.02 26 86.7 0.003
Same grade 29 96.7 19 63.3 0.32 4 13.3 0.45
Worsened 0 0 0 0 – 0 0 -
After 2 months Improved 0 0 15 50 0.06 20 66.7 0.001
Same grade 28 93.3 15 50 0.31 9 30 0.53
Worsened 2 6.7 0 0 – 1 0 0.92
After 3 months Improved 2 6.7 15 50 0.03 18 60 0.03
Same grade 27 90 14 46. 0.62 10 33.3 0.61
Worsened 1 3.3 0 0 – 2 6.7 0.71
After 6 months Improved 2 6.7 14 46.7 0.002 20 66.7 0.002
Same grade 25 83.3 14 46.7 0.35 10 33.3 0.92
Worsened 2 6.7 0 0 – 0 0 0.92
After 9 months Improved 0 0 12 40 0.006 20 66.7 0.001
Same grade 26 86.7 16 53.3 0.3 10 33.3 0.46
Worsened 2 6.7 0 0 – 0 0 0.83
After 12 months Improved 1 3.3 11 36.7 0.003 20 66.7 0.001
Same grade 23 76.7 16 53.3 0.42 8 26.7 0.46
Worsened 1 3.3 0 0 – 0 0 0.92
Fig. 8 a Progress of degree of ascites in group III (control group). b Progress of the degree of ascites in group I (single infusion). c Progress of
degree of ascites in group II (repeated infusion)
Zekri et al. Stem Cell Research & Therapy  (2015) 6:118 Page 11 of 14
Table 8 Progress of hepatic encephalopathy in the studied groups at baseline and after 3, 6, 9 and 12 months of follow-up
Timing of hepatic encephalopathy Number of episodes Single infusion (Group I) Repeated infusion (Group II) Control group (Group III) P value
At baseline No 18 60 % 17 56.7 % 16 53.3 % 0.9
Once 5 16.7 % 8 26.7 % 9 30 %
Repeated 7 23.3 % 5 16.7 % 5 16.7 %
Total 30 100 % 30 100 % 30 100 %
After 3 months No 28 93.3 % 29 96.7 % 26 86.7 % 0.13
Once 1 3.3 % 1 3.3 % 4 13.3 %
Repeated 0 0 % 0 0 % 0 0 %
Mortality 1 3.3 % 0 0 % 0 0 %
Total 30 100 % 30 100 % 30 100 %
After 6 months No 25 83.3 % 26 86.7 % 23 76.7 %
Once 3 10 % 4 13.3 % 6 20 %
Repeated 0 0 % 0 0 % 0 0 %
Mortality 2 6.7 % 0 0 % 1 3.3 %
Total 30 100 % 30 100 % 30 100 %
After 9 months No 27 90 % 27 90 % 23 76.7 % 0.37
Once 1 3.3 % 1 3.3 % 5 16.7 %
Repeated 0 0 % 2 6.7 % 0 0 %
Mortality 2 6.7 % 0 0 % 2 6.7 %
Total 30 100 % 30 100 % 30 100 %
After 12 months No 26 86.7 % 25 83.3 % 24 80 % 0.47
Once 1 3.3 % 2 6.7 % 1 3.3 %
Twice 0 0 % 1 3.3 % 0 0 %
Mortality 3 10 % 2 6.7 % 5 16.7 %
Total 30 100 % 30 100 % 30 100 %
Zekri et al. Stem Cell Research & Therapy  (2015) 6:118 Page 12 of 146.7 % (two patients) in the control group. Further inves-
tigations for this patient by triphasic CT scan showed no
hepatic focal lesions and an AFP level of 19 ng/ml. Pa-
tients in G-II (repeated infusion) showed no incidence of
PVT throughout the follow-up period.
Although some studies in the literature have men-
tioned a possible carcinogenic effect of BMSC infusion
in patients with chronic liver diseases, especially if
in vitro pre-expanded [11], our data showed that after
12 months of follow-up by ultrasonography and s-AFP
only one patient (3.3 %) in G-I (single infusion) and
none in G-II (repeated infusion) were diagnosed with
HCC compared with two patients (6.7 %) in the control
group. Our results are comparable with those of Levicar
et al. [14], who showed absence of any focal lesions in
five patients treated by stem cell therapy who were
followed-up by CT scan and serum AFP for 18 months,
indicating that the stem cell product used was safe in
the short term and over the long term, by absence of
tumour formation. Our results suggest that combined
application of HSCs by infusion into the portal vein and
the peripheral veins bears the potential for augmentingliver regeneration in the clinical setting and can be used
in the treatment of decompensated liver cirrhosis.
The HSCs can be delivered via different routes; each
of which has its own advantages and disadvantages. The
ideal strategy for stem cell delivery is that it should be
easy to perform, minimally invasive, has very little side
effects, has high cell survival and should be based on
clinical settings. Moreover, under certain circumstances,
the combination of more than one method may be con-
sidered [29, 30].
Two recently published meta-analyses have confirmed
our previous and current data regarding the beneficial
effect of stem cell therapy for end-stage liver disease
patients and show almost the same results as ours.
However, our current study is a step ahead of any pre-
vious published data by using a double stem cell infu-
sion technique to extend the beneficial effect for more
than 1 year [31, 32].
To our knowledge, the current study is the first trial
investigating a second session of HSC infusion in Egyptian
patients with HCV-related liver cell failure. Our results
provide evidence for the first time that two infusions with
Zekri et al. Stem Cell Research & Therapy  (2015) 6:118 Page 13 of 14HSC result in more sustained improvement in liver func-
tions and quality of life during 12-months follow-up than
a single infusion.
A point of criticism for the current study could be the
lack of a control group of patients who received G-CSF
alone, especially in the presence of several studies dem-
onstrating a beneficial effect of G-CSF alone [33, 34].
One reason for not using G-CSF alone in the current
study is that we have previously shown that the content
of stem cells in end-stage liver disease patients is usually
very low (1–3 % only). This amount is not sufficient for
stem cell treatment in those patients and does not in-
duce much improvement at the clinical and/or biochem-
ical levels. However, with G-CSF the stem cell content
increased to about 50–75 %, which provided the proper
amount required for stem cell transplantation and differ-
entiation even after purification of CD133+ and CD34+
cells. In addition, the main aim of the current study was
to assess the beneficial effect (clinical and biochemical)
of repeated MSC infusion, administered 4 months apart,
as compared with single infusion and a control group.
Conclusions
Repeated HSC infusions give more sustained clinical effi-
cacy and improvement in liver functions and quality of
life during 12-month follow-up compared with single
HSC infusion. Accordingly, stem cell therapy could be a
promising therapeutic modality in patients with end-
stage liver disease, which may replace or decrease the
need for whole organ transplantation in the future, espe-
cially if gene manipulation of the stem cells makes them
able to resist viral infection or HCC development.
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